Interview: Jung Hyun Ho – Founder & CEO, Medytox – Korea
Medytox is the most valuable pharmaceutical business in Korea, with a highly successful botulinum toxin product on the market, and can only grow further when they finish development of their…
Medytox has successfully developed the fourth botulinum toxin type A product in the world, and today exports products to more than 60 countries including Japan, Thailand, India, and Brazil. Medytox has been making efforts to penetrate into the US and European market in the near future to show its presence as a leading global biopharmaceutical company.
Medytox is at the forefront of the Korean biopharmaceutical industry, thanks to its excellent R&D capabilities with top-teir biotechnologists, and to its state-of-the-art operations and production facilties. Moreover, Medytox is going to become a frontier in the field of biopharmaceuticals due to its passion and courage to embrace global challenges.
Contact Details
78, Gangni 1-gil, Ochang-eup, Cheongwon-gu,
Cheongju-si, Chungcheongbuk-do
Korea
Medytox is the most valuable pharmaceutical business in Korea, with a highly successful botulinum toxin product on the market, and can only grow further when they finish development of their…
Olive Healthcare is a startup developing wellness and medical devices services for the quantitative measurement of body composition, an integral part of the new healthcare paradigm based on prevention. Here,…
A Korean research team at Ulsan National Institute of Science and Technology (UNIST) have developed a cunning technology for treatments that attack cancer cells. Treatments that travel through the…
From Wednesday 31st October to Friday 2nd November, Seoul hosted the KoNECT-MFDS International conference, promoting South Korea’s clinical research capabilities on a global platform. The fourth of its kind, the…
Celltrion Healthcare, the marketing arm of the biopharmaceutical company Celltrion won a huge deal in France last Friday (2nd November 2018) with big tenders for Herzuma, a biosimilar of Roche’s…
Korea is fast becoming a big player in the pharmaceutical industry, especially within the biotech arena. With 4% of the total pipelines in the world, the country is showing strong…
Korean Pharma company, Hanmi has won orphan drug status this week from the US Food and Drug Administration (FDA) for HM43239, a drug for the treatment of acute myeloid leukaemia…
Local flagship company Boryung has found success with its newly developed angiotension receptor blocker (ARB) Kanarb. Nine molecules currently exist worldwide in this category of antihypertensives, and Kanarb is currently…
The growth of clinical trials in Korea has been remarkable in recent years. The number of clinical trials performed by multinationals has shot up from five in 2000 to 303…
Korea’s economy has been dominated for decades by chaebols, large family-owned business conglomerates like Samsung, Hyundai, and LG, known for their hierarchical structures and success in Korea’s traditional sectors. However,…
Medytox is the most valuable pharmaceutical business in Korea, with a highly successful botulinum toxin product on the market, and can only grow further when they finish development of their…
“When I left Janssen, I never imagined joining a Korean company,” recalls Choi Tae-Hung, sipping a freshly brewed yujacha tea in his office on a crisp autumn morning as he…
Minister Moon discusses the results of his recent state visit to the Middle East with Korea’s President, and Korea’s assets and potential as a global healthcare partner in developing and…
See our Cookie Privacy Policy Here
